{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-25-000008","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.330597+00:00","generated_at":"2026-05-26T23:23:24.533163+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arvinas reports Q4/FY2024 results; VERITAC-2 Phase 3 topline data expected in Q1 2025","bullets":["Cash, cash equivalents and marketable securities $1,039.4M as of Dec 31, 2024; revenue $263.4M.","VERITAC-2 Phase 3 monotherapy topline data in ER+/HER2- mBC anticipated in 1Q25; two new Phase 3 combos planned in 2025.","ARV-102 (LRRK2 degrader) Phase 1 in Parkinson's initiated; SAD data in healthy volunteers to be presented at AD/PD in April 2025.","Alex Santini appointed interim Chief Commercial Officer effective January 17, 2025.","Cash runway sufficient into 2027; VERITAC-3 (vepdegestrant+palbociclib) discontinued beyond study lead-in."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-25-000008","json":"https://secwatch.observer/filing/0001655759-25-000008.json","markdown":"https://secwatch.observer/filing/0001655759-25-000008.md","text":"https://secwatch.observer/filing/0001655759-25-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575925000008/0001655759-25-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575925000008/arvn-20250211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:23:24.533163+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}